These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 25132752)

  • 41. Seven-day quintuple regimen as a rescue therapy for Helicobacter pylori eradication.
    Mansour-Ghanaei F; Joukar F; Naghipour MR; Forouhari A; Saadat SM
    World J Gastroenterol; 2015 Jan; 21(2):661-6. PubMed ID: 25593496
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.
    Molina-Infante J; Pazos-Pacheco C; Vinagre-Rodriguez G; Perez-Gallardo B; Dueñas-Sadornil C; Hernandez-Alonso M; Gonzalez-Garcia G; Mateos-Rodriguez JM; Fernandez-Bermejo M; Gisbert JP
    Helicobacter; 2012 Aug; 17(4):269-76. PubMed ID: 22759326
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 'Rescue' therapies for the management of Helicobacter pylori infection.
    Di Mario F; Cavallaro LG; Scarpignato C
    Dig Dis; 2006; 24(1-2):113-30. PubMed ID: 16699270
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study.
    Liang X; Xu X; Zheng Q; Zhang W; Sun Q; Liu W; Xiao S; Lu H
    Clin Gastroenterol Hepatol; 2013 Jul; 11(7):802-7.e1. PubMed ID: 23376004
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial.
    Tai WC; Liang CM; Kuo CM; Huang PY; Wu CK; Yang SC; Kuo YH; Lin MT; Lee CH; Hsu CN; Wu KL; Hu TH; Chuah SK
    J Antimicrob Chemother; 2019 Jun; 74(6):1718-1724. PubMed ID: 30768161
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of four different regimens against Helicobacter pylori as a first-line treatment: A prospective, cross-sectional, comparative, open trial in Chinese children.
    Zhou Y; Ye Z; Wang Y; Zhang Y; Tang Z; Yan W; Jiang Y; Huang Y
    Helicobacter; 2020 Apr; 25(2):e12679. PubMed ID: 31958193
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line.
    Di Caro S; Fini L; Daoud Y; Grizzi F; Gasbarrini A; De Lorenzo A; Di Renzo L; McCartney S; Bloom S
    World J Gastroenterol; 2012 Oct; 18(40):5669-78. PubMed ID: 23155306
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Helicobacter pylori eradication regimens in an antibiotic high-resistance European area: A cost-effectiveness analysis.
    Papaefthymiou A; Liatsos C; Georgopoulos SD; Apostolopoulos P; Doulberis M; Kyriakos N; Giakoumis M; Papadomichelakis M; Galanopoulos M; Katsinelos P; Rokkas T; Kountouras J
    Helicobacter; 2020 Feb; 25(1):e12666. PubMed ID: 31692137
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial.
    Hsu PI; Tsai FW; Kao SS; Hsu WH; Cheng JS; Peng NJ; Tsai KW; Hu HM; Wang YK; Chuah SK; Chen A; Wu DC
    Am J Gastroenterol; 2017 Sep; 112(9):1374-1381. PubMed ID: 28719592
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real-world practice of Helicobacter pylori management: A survey among physicians in Southeast Asia.
    Quach DT; Vilaichone RK; Luu MN; Lee YY; Ang TL; Miftahussurur M; Aye TT; Basir DN; Vutha K; Vannarath S; Sollano JD; Mahachai V
    Helicobacter; 2023 Dec; 28(6):e13018. PubMed ID: 37634226
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 10-Year Trends in Helicobacter pylori Eradication Rates by Sitafloxacin-Based Third-Line Rescue Therapy.
    Mori H; Suzuki H; Matsuzaki J; Masaoka T; Kanai T
    Digestion; 2020; 101(5):644-650. PubMed ID: 31387107
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 14-Day High-Dose Amoxicillin- and Metronidazole-Containing Triple Therapy With or Without Bismuth as First-Line Helicobacter pylori Treatment.
    Luo L; Ji Y; Yu L; Huang Y; Liang X; Graham DY; Lu H
    Dig Dis Sci; 2020 Dec; 65(12):3639-3646. PubMed ID: 32020360
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South Korea.
    Kang KK; Lee DH; Oh DH; Yoon H; Shin CM; Park YS; Kim N; Jung HC
    World J Gastroenterol; 2014 Jun; 20(22):6932-8. PubMed ID: 24944485
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg).
    Nyssen OP; Perez-Aisa A; Rodrigo L; Castro M; Mata Romero P; Ortuño J; Barrio J; Huguet JM; Modollel I; Alcaide N; Lucendo A; Calvet X; Perona M; Gomez B; Gomez Rodriguez BJ; Varela P; Jimenez-Moreno M; Dominguez-Cajal M; Pozzati L; Burgos D; Bujanda L; Hinojosa J; Molina-Infante J; Di Maira T; Ferrer L; Fernández-Salazar L; Figuerola A; Tito L; de la Coba C; Gomez-Camarero J; Fernandez N; Caldas M; Garre A; Resina E; Puig I; O'Morain C; Megraud F; Gisbert JP
    Helicobacter; 2020 Oct; 25(5):e12722. PubMed ID: 32656898
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of Helicobacter pylori infection: current status and future concepts.
    Yang JC; Lu CW; Lin CJ
    World J Gastroenterol; 2014 May; 20(18):5283-93. PubMed ID: 24833858
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High Efficacy of Levofloxacin-Dexlansoprazole-Based Quadruple Therapy as a First Line Treatment for Helicobacter pylori Eradication in Thailand.
    Prapitpaiboon H; Mahachai V; Vilaichone RK
    Asian Pac J Cancer Prev; 2015; 16(10):4353-6. PubMed ID: 26028098
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori.
    Gisbert JP; Calvet X
    Aliment Pharmacol Ther; 2011 Sep; 34(6):604-17. PubMed ID: 21745241
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bismuth-based quadruple therapy following H. pylori eradication failures: a multicenter study in clinical practice.
    Zullo A; De Francesco V; Bellesia A; Vassallo R; D'Angelo A; Scaccianoce G; Sacco R; Bresci G; Eramo A; Tanzilli A; Ridola L; Alvaro D; Londoni C; Brambilla G; Manta R; Di Ciaula A; Portincasa P
    J Gastrointestin Liver Dis; 2017 Sep; 26(3):225-229. PubMed ID: 28922433
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy.
    Chen Q; Zhang W; Fu Q; Liang X; Liu W; Xiao S; Lu H
    Am J Gastroenterol; 2016 Dec; 111(12):1736-1742. PubMed ID: 27670603
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China.
    Xie Y; Zhu Z; Wang J; Zhang L; Zhang Z; Lu H; Zeng Z; Chen S; Liu D; Lv N;
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.